Lexicon Pharmaceuticals (NASDAQ:LXRX) was downgraded by equities researchers at G.Research from a “buy” rating to a “hold” rating in a research note issued on Wednesday, December 11th, Stock Target Advisor reports. G.Research also issued estimates for Lexicon Pharmaceuticals’ FY2019 earnings at $0.95 EPS, FY2020 earnings at ($1.95) EPS, FY2021 earnings at ($1.25) EPS, FY2022 earnings at ($0.60) EPS and FY2023 earnings at ($0.15) EPS.
A number of other research analysts have also weighed in on LXRX. Wedbush reaffirmed a “buy” rating and set a $17.00 price objective on shares of Lexicon Pharmaceuticals in a research report on Monday, December 2nd. Gabelli lowered Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, December 11th. They noted that the move was a valuation call. BidaskClub raised Lexicon Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, December 7th. Citigroup lowered Lexicon Pharmaceuticals from a “buy” rating to a “neutral” rating and raised their price objective for the company from $3.00 to $4.00 in a research report on Friday, November 8th. Finally, ValuEngine raised Lexicon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, October 2nd. Eight equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $6.45.
Shares of NASDAQ:LXRX traded up $0.02 during trading on Wednesday, hitting $3.96. The stock had a trading volume of 742,660 shares, compared to its average volume of 1,022,387. Lexicon Pharmaceuticals has a 12 month low of $1.13 and a 12 month high of $8.39. The company has a market capitalization of $418.71 million, a PE ratio of -3.47 and a beta of 1.02. The firm’s fifty day moving average is $4.16 and its 200 day moving average is $3.69. The company has a quick ratio of 8.01, a current ratio of 8.11 and a debt-to-equity ratio of 1.42.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its earnings results on Thursday, November 7th. The biopharmaceutical company reported $2.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.31 by $0.80. Lexicon Pharmaceuticals had a return on equity of 2,372.40% and a net margin of 49.78%. The firm had revenue of $294.45 million during the quarter, compared to analyst estimates of $12.00 million. During the same quarter in the prior year, the company earned ($0.26) EPS. The business’s revenue was up 4124.5% compared to the same quarter last year. Equities research analysts expect that Lexicon Pharmaceuticals will post 1.01 EPS for the current fiscal year.
Several institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its holdings in shares of Lexicon Pharmaceuticals by 8.1% in the 2nd quarter. Vanguard Group Inc. now owns 4,240,111 shares of the biopharmaceutical company’s stock worth $26,670,000 after purchasing an additional 319,382 shares in the last quarter. First Manhattan Co. boosted its stake in shares of Lexicon Pharmaceuticals by 7.3% in the 2nd quarter. First Manhattan Co. now owns 2,949,979 shares of the biopharmaceutical company’s stock worth $18,555,000 after buying an additional 201,393 shares during the last quarter. Millennium Management LLC boosted its stake in shares of Lexicon Pharmaceuticals by 4.5% in the 3rd quarter. Millennium Management LLC now owns 1,220,629 shares of the biopharmaceutical company’s stock worth $3,674,000 after buying an additional 53,092 shares during the last quarter. State Street Corp boosted its stake in shares of Lexicon Pharmaceuticals by 1.5% in the 3rd quarter. State Street Corp now owns 952,606 shares of the biopharmaceutical company’s stock worth $2,867,000 after buying an additional 13,654 shares during the last quarter. Finally, Pictet Asset Management Ltd. boosted its stake in shares of Lexicon Pharmaceuticals by 9.6% in the 3rd quarter. Pictet Asset Management Ltd. now owns 729,876 shares of the biopharmaceutical company’s stock worth $2,197,000 after buying an additional 64,100 shares during the last quarter. 96.24% of the stock is owned by institutional investors and hedge funds.
Lexicon Pharmaceuticals Company Profile
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.
Further Reading: How Does the Quiet Period Work?
Receive News & Ratings for Lexicon Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.